课题基金 / 基金详情

ABX IL8 IN TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS

ABX IL8 IN TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS
ABX IL8 治疗中度至重度斑块状银屑病
批准号：
6297042
负责人：
Sewon Kang
金额：
$0.02万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6297042
关键词：
clinical research clinical trials dosage drug administration rate /duration drug screening /evaluation human subject human therapy evaluation interleukin 8 psoriasis skin disorder chemotherapy

项目摘要

项目成果

Sewon Kang的其他基金

相似基金

相关文献

中文摘要
翻译
主要目的是确定单次静脉注射剂量ABX-IL8治疗斑块型银屑病患者的安全性，斑块型银屑病患者的体表面积大于3%。这是一项多中心、随机、安慰剂对照、剂量递增的临床试验，旨在检查单次静脉输注ABX-IL8对中度至重度斑块型银屑病患者的安全性。下一个剂量水平将根据方案中规定的累积安全信息确定。
英文摘要
The primary objective is to determine the safety of a single IV dose of ABX-IL8 in the treatment of patients with plaque psoriasis involving greater than 3% of the body surface area. This is a multicenter, randomized, placebo-controlled, dose rising clinical trial examining the safety of administering a single intravenous infusion of ABX-IL8 in patients with moderate to severe plaque psorasis. The next dose level will be based on accumulated safety information as defined in the protocol.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
P3: Infrared Irradiation and Scleroderma Skin
OPEN LABEL STUDY OF TETRATHIOMOLYBDATE IN TREATMENT OF PSORIASIS VULGARIS
Univ of Michigan Multidisciplinary Clinical Resea**(RMI)
University of Michigan Multidisciplinary Clinical Research (RMI)
海外基金